Objectives: The anti-leprosy drug clofazimine has been shown to have antimicrobial activity against Mycobacterium tuberculosis and has been associated with treatment-shortening activity in both clinical and preclinical studies of TB chemotherapy. However, a reported lack of early bactericidal activity (EBA) in TB patients has raised questions regarding the usefulness of clofazimine as an anti-TB drug. Our objective was to systematically evaluate the EBA of clofazimine in vitro and in vivo to provide insight into how and when this drug exerts its antimicrobial activity against M. tuberculosis.
Introduction
The standard, WHO-recommended first-line regimen for the treatment of TB is a 6 month multidrug combination: a 2 month intensive phase of daily rifampicin, isoniazid, ethambutol and pyrazinamide followed by a 4 month continuation phase of daily rifampicin and isoniazid. 1 In TB patients, as well as in the aerosol-infected mouse model of TB chemotherapy, this regimen must be administered for the entire 6 months to achieve relapsefree cure. 2, 3 Although highly efficacious, its duration might preclude strict adherence and lead to treatment failure with the selection of drug-resistant Mycobacterium tuberculosis; thus a key issue in current TB treatment is to shorten its duration.
In recent years, a number of clinical studies have indicated that the anti-leprosy drug clofazimine may contribute treatmentshortening activity when included in multidrug regimens for the treatment of patients with MDR-TB, 4 -8 and, in May 2016, the WHO released new guidelines for the treatment of MDR-TB, referred to as 'the shorter MDR-TB regimen', in which clofazimine was included in the recommended standardized regimen. 9 In experimental chemotherapy studies in mouse models of both drug-susceptible and drug-resistant TB, where the specific impact of including clofazimine in treatment regimens could be directly assessed, clofazimine was shown to contribute significant bactericidal and treatment-shortening activity. 10, 11 Because of this growing body of evidence suggesting that clofazimine may be an effective drug for TB treatment, the Global Alliance for TB Drug Development supported a Phase 2A randomized clinical trial to examine the 14 day early bactericidal activity (EBA) of clofazimine alone or in combination with pyrazinamide and bedaquiline and/ or pretomanid in treatment-naive patients with sputum smearpositive TB. 12 Despite administration of loading doses of 300 mg daily for the first 3 days followed by the usual 100 mg daily dose on days 4 -14, no EBA was observed in the patients treated with clofazimine alone, i.e. the bacterial load in the sputum was no different at the end of treatment than at the start of treatment. Furthermore, no additive bactericidal activity was conferred by the addition of clofazimine in patients treated with multidrug regimens. These findings raised concerns about the use of clofazimine in TB treatment, although it is well known that the overall antimicrobial efficacy of drugs and regimens cannot be accurately assessed from a 14 day EBA study, and that other key anti-TB drugs such as pyrazinamide and rifampicin may also have no or poor 14 day EBA. 12, 13 Even in the experimental studies in mouse models of TB treatment, it has been observed that clofazimine has little activity in the first 1-2 weeks of treatment, but then contributes robust bactericidal activity. 11, 14 As clofazimine has shown such promise for the shortening of TB treatment in long-term studies in both humans and in mice, and is now included in the WHO-recommended regimen for treatment of MDR-TB, 9 we considered that a better understanding of why clofazimine has this apparent delayed bactericidal activity may provide valuable insight regarding how and when the drug is working. Such knowledge could help guide the design of clinical studies, for example by providing preclinical data useful for the selection of critical timepoints and/or setting expectations regarding the time frame of clofazimine's anti-TB activity. Relatively little is known about clofazimine's mechanism of action. 15, 16 Therefore, we conducted a series of in vitro and in vivo experiments to dissect the EBA of clofazimine against M. tuberculosis.
Materials and methods
All experimental work was performed at the KwaZulu-Natal Research Institute for TB-HIV, Durban, South Africa, and the Biomedical Resources Unit, College of Health Sciences, University of KwaZulu-Natal, Westville, South Africa. Work with live bacteria and infected animals was performed in biosafety level 3 facilities.
Ethics
All animal procedures were approved by the Animal Ethics Sub-Committee of the University of KwaZulu-Natal (reference numbers 068/13/Animal and 025/14/Animal). Animals were cared for in accordance with South African national guidance.
Animals
Female BALB/c mice (age 6 -8 weeks, mass 18 -20 g) obtained through in-house breeding were used in all experiments. The BALB/c mouse model of TB chemotherapy, specifically for EBA assessment, has previously been developed by our group. 17 The mice were housed in individually ventilated cages (five mice per cage) with sterile wood shavings as bedding material; room temperature was maintained at 22 -248C with a 12 h light/dark cycle. The mice were sacrificed by either cardiac puncture or cervical dislocation, both under anaesthesia; blood and lungs were collected as appropriate.
Bacteria
All experiments with live bacteria used stock cultures of M. tuberculosis strain H37Rv (ATCC 27294). These stocks had been prepared from broth culture grown to an OD 600 of 1.0 and then frozen (2808C) in 1 mL aliquots. Prior to starting an experiment, stock cultures were thawed and added to growth medium: Middlebrook 7H9 broth with 10% (v/v) Middlebrook OADC supplement and 0.05% (v/v) Tween 80. The fresh cultures were then used for experiments when the OD 600 reached 1.0 (corresponding to 10 7 -10 8 cfu/mL).
Drug preparation and administration
All drugs were purchased from Sigma. For in vitro experiments, isoniazid and clofazimine were first dissolved in DMSO to generate stock solutions of 1 and 0.2 mg/mL, respectively. For in vivo experiments, isoniazid was dissolved in distilled water and clofazimine was suspended in a 0.05% (w/v) agarose solution. Drugs were prepared to deliver the desired dose in 0.2 mL, administered to mice by oral gavage. Drugs were prepared weekly and stored at 48C.
In vitro EBA experiments
The DMSO stock solutions of isoniazid and clofazimine were added to Middlebrook 7H9 broth supplemented with 10% (v/v) Middlebrook OADC, but without Tween 80. The drug-containing broth was then serially diluted . Drug-containing and drug-free control broth was prepared in vials to a final volume of 10 mL. The M. tuberculosis culture was adjusted to an OD 600 of 1.0, then diluted 10-fold in broth and 100 mL of this diluted bacterial suspension was added to each vial of the drug-containing and no-drug control broth. All samples were vortexed and 1 mL from the drug-free control broth vials was removed to determine the initial (day 0) cfu counts. All samples were incubated (with agitation) at 378C. Cultures were vortexed for 30 s and then 1 mL was removed from each vial after 1, 2, 7 and 14 days (one replicate) or after 1, 2, 4, 7 and 14 days (two replicates) of incubation to determine cfu counts. At each timepoint, samples were serially diluted (10-fold dilutions) to the 10 24 dilution and 0.5 mL of each dilution was plated on a non-selective 7H11 agar plate. Plates were incubated at 378C and cfu were counted after 4 weeks of incubation. The dilution that yielded cfu counts closest to 50 was used to calculate the total cfu/mL. cfu counts were log-transformed and the EBA was defined as the decline in log 10 cfu/mL/day.
In vivo EBA experiments
Our group has previously developed a mouse model of EBA studies for TB treatment. 17 Two hundred and forty-five mice were aerosol-infected with M. tuberculosis (using culture with an OD 600 of 1.0) in two infection runs within a Glas-Col Inhalation Exposure System, per the manufacturer's instructions and with 10 mL of culture per run to implant 3.5-4.0 log 10 cfu/lung. The day after infection, five mice from each infection run were sacrificed to determine the bacterial lung implantation. Five mice from each infection run were kept until the start of treatment to assess the cfu counts at that time, and all other mice were randomized into one of the nine treatment groups: no drug (negative control); isoniazid at 10 mg/kg/ day (positive control); and clofazimine at 100, 50, 25, 12.5, 6.25, 3.125 or 1.5625 mg/kg/day. Treatment was initiated 7 days after infection for the following reasons: (i) as we anticipated that clofazimine would not have EBA, a traditional acute infection model, where the mice are infected with a relatively high inoculum of bacteria (3.5 -4.0 log 10 cfu/lung) Ammerman et al.
and treatment is started 2 weeks after infection, could result in death of the clofazimine-treated mice before the end of the 2 week study; (ii) use of a chronic model (where mice are infected with a lower implantation, around 2 log 10 cfu/lung, and treatment is initiated 4-6 weeks after infection) would limit our ability to detect antimicrobial activity, as the untreated mice would have a stabilized lung infection, precluding detection of bacteriostatic activity; and (iii) starting treatment 7 days after infection would ensure that we could detect any antimicrobial activity, as the bacterial load in the mouse lungs should increase throughout the 14 days of the experiment-thus bacteriostatic or bactericidal activity of drugs would be clearly evident in this model. Treatment was administered daily for 14 days (including the weekends). Groups of five mice per treatment group were sacrificed after 2, 4, 7, 10 and 14 days of treatment (with the sacrifice timed 24 h after administration of the drug dose at the given timepoint). Lungs were dissected from all mice and transferred to 15 mL conical tubes containing 2.5 mL of sterile PBS. The lungs were kept for 2 -4 days at 48C before homogenization in 2 mL glass mortar and pestle homogenizers. Lung homogenates were serially diluted (10-fold dilutions) down to the 10 25 dilution and a 0.5 mL aliquot of each dilution was plated onto both a selective 7H11 agar plate supplemented with 0.4% activated charcoal (to limit and detect drug carryover) 18 and a non-charcoalcontaining (i.e. plain) selective 7H11 agar plate. Plates were incubated at 378C and cfu were counted after 4 weeks of incubation. The dilution that yielded cfu counts closest to 50 was used to calculate the total cfu/lung, using the cfu counts from either the plain or charcoal-containing plate, whichever had the higher count. On day 14, blood was collected from all mice (cardiac puncture under anaesthesia) prior to lung dissection. The blood from each individual mouse was transferred to a microcentrifuge tube, left at room temperature for at least 20 min and then spun at 18 000 g for 10 min. For each sample, a 20 mL aliquot of serum was removed and transferred into a 2 mL screw-cap tube containing 180 mL of ethanol, then vortexed for 30 s and stored at 2808C until analysis. Serum clofazimine concentrations were determined by LC-MS, as previously described. 11 
Statistical analyses
For the in vivo EBA experiment, cfu count data were analysed using twoway ANOVA corrected with Tukey's test for multiple comparisons. Serum clofazimine concentrations were analysed using linear trend one-way ANOVA (dose -response) and using one-way ANOVA corrected with Tukey's test for multiple comparisons (inter-dose comparisons).
Results

In vitro EBA of clofazimine
One of the striking pharmacokinetic characteristics of clofazimine is that the drug, which is highly lipophilic, accumulates to extremely high levels in the tissues. 14, 19 We hypothesized that host tissues may need to reach a saturation level before there is enough free clofazimine available to exert bactericidal activity against M. tuberculosis, and clofazimine therefore would exhibit EBA in vitro where the bacteria are immediately exposed to free drug. To assess this, we conducted a 14 day EBA study of clofazimine against M. tuberculosis in broth culture. Isoniazid was used as the positive control, and, as expected, exposure to this drug resulted in rapid killing of M. tuberculosis (Figure 1a -c; all raw cfu data are presented in Table S1 , available as Supplementary data at JAC Online), with EBA 0 -2 .1.1 at concentrations above the MIC (Table 1) . Also as expected, biphasic killing of isoniazid was observed, with increasing cfu counts towards the end of the experiment, likely due to the selection of isoniazid-resistant bacteria. 20 In contrast, clofazimine did not exert any apparent activity against M. tuberculosis during the first 2 -4 days of exposure, but after 1 week exhibited concentration-dependent antimicrobial activity: bacteriostatic activity at concentrations at or below the 0.25 mg/L MIC and bactericidal activity at concentrations above the MIC (Figure 1d -f and Table S1 ). The average EBA 0 -2 value for clofazimine at any concentration was close to zero, while the EBA 7 -14 increased with each concentration, reaching 0.362 at the highest (2.0 mg/L) concentration (Table 1) .
In vivo EBA of clofazimine
Although in vitro antimicrobial activity was delayed with all concentrations of clofazimine tested, more killing was observed at day 7 with the higher drug concentrations. Thus, it may be possible that clofazimine needs to accumulate within the bacterial cells (or saturate the lipid-rich bacterial cell wall) before it can exert activity, in which case the delay could be overcome, at least partially, by increasing the dose administered. To carefully dissect the early activity of clofazimine in vivo, we conducted a dose-ranging 14 day EBA study in the mouse model previously developed by our group. 17 In this experiment, mice were infected by aerosol with M. tuberculosis, implanting an average of 3.97 [standard deviation (SD) ¼ 0.11] log 10 cfu in the lungs. Treatment was initiated 1 week after infection (day 0), when the bacterial burden in the lungs had reached 4.98 (SD ¼ 0.23) log 10 cfu, when the bacteria were actively multiplying, as in the in vitro EBA experimental conditions. After 14 days of treatment, the serum clofazimine concentrations were clearly and significantly dose dependent (P,0.0001), ranging from an average of 1.63 mg/L at the highest daily dose (100 mg/kg) to 0.10 mg/L at the lowest daily dose (1.5 mg/kg) ( Figure 2a ). As expected, in untreated negative control mice, the lung cfu counts continued to increase throughout the experiment, reaching 7.77 (SD¼ 0.40) log 10 cfu by day 14, while in the positive control mice treated with isoniazid, the lung cfu counts declined throughout treatment, falling to 3.26 log 10 cfu by day 14 (Figure 2b ; all raw cfu data are presented in Table S2 ).
In mice receiving any dose of clofazimine, the lung bacterial load continued to increase during the first 7 days of treatment ( Figure 2b and Table S2 ). After 10 days of clofazimine administration, the cfu counts in the lungs of mice receiving the three highest doses (100, 50 and 25 mg/kg) were significantly lower than the cfu counts in the lungs of the no-drug control mice (P,0.0001) and in the lungs of mice receiving any of the other doses of clofazimine (P, 0.01). However, no significant differences were observed in lung cfu counts between mice receiving clofazimine at 100, 50 or 25 mg/kg; significant differences were also not observed between the mice receiving 12.5, 6.25, 3.1 or 1.5 mg/kg. At the 14 day timepoint, the lung cfu counts had significantly declined in mice receiving 100 or 50 mg/kg compared with the 10 day timepoint, while the counts remained stable in mice receiving clofazimine at 25 mg/kg (and remained significantly lower than those in the no-drug control mice, P,0.0001). For all other doses of clofazimine administered, the lung cfu counts had continued to increase and were not significantly different from those in the no-drug control mice. No differences in lung gross morphology were observed across any of the treatment groups or timepoints ( Figure S1 ).
Although clofazimine administered at 50 or 100 mg/kg exhibited bactericidal activity during the second week of treatment, Delayed anti-tuberculosis activity of clofazimine JAC with EBA 7 -14 values of 0.064 and 0.097, respectively (Table 2) , the bacterial lung burden in mice receiving any dose of clofazimine was still higher at the 14 day timepoint than the lung cfu counts at the start of treatment (Figure 2b and Table S2 ). Thus, the overall 14 day EBA (EBA 0 -14 ) was negative for all doses of clofazimine administered, whereas the EBA 0 -14 for isoniazid was 0.122 (Table 2) .
Drug carryover
The accumulation of clofazimine in the tissues can lead to drug carryover from the homogenized lungs, which can prevent the growth of M. tuberculosis on the agar plates. 10, 11, 14 To detect and adjust for any drug carryover, mouse lung homogenates from the in vivo EBA study were plated in parallel on both plain 7H11 selective agar and on 7H11 selective agar supplemented with 0.4% activated charcoal (to adsorb the drug). Although clofazimine was administered for only 14 days in this study, carryover was already observed after 2 days of treatment (i.e. after two doses of clofazimine) in lung homogenates from mice receiving the 50 or 100 mg/kg doses; bacterial growth was inhibited on all plain plates inoculated with undiluted lung homogenate, while the charcoal-containing plates inoculated with the same homogenates were covered with bacterial lawns (Table S2 ). After 10 days of treatment, carryover was observed in the undiluted lung homogenates for mice receiving 12.5 mg/kg and greater doses, and, after 14 days of treatment, carryover was also observed in the undiluted lung homogenates from mice receiving 6.25 mg/kg clofazimine. During this 2 week study, carryover was not observed in the undiluted lungs from mice receiving 3.1 or 1.5 mg/kg clofazimine, and no carryover was observed in any lung homogenates plated after one 10-fold dilution (Table S2) .
Discussion
As has been reported in humans 12 and in mice, 14 our data confirm that clofazimine does not have EBA in vivo against M. tuberculosis. However, our careful dissection of clofazimine's activity against M. tuberculosis during the first 2 weeks of exposure has provided several key insights regarding how and when the drug exerts its antimicrobial activity.
As clofazimine is well known to accumulate to extremely high levels in the tissues, 14 we considered that the delay in clofazimine's antimicrobial activity could represent a saturation period in the host, and thus that antimicrobial activity would only be observed after a threshold level was achieved. However, even at concentrations up to four times the MIC, clofazimine did not exhibit any antimicrobial activity in vitro against M. tuberculosis during the first 4 days of exposure (Figure 1) , thus indicating that binding to host tissues was not solely responsible for the delayed activity. Mothiba et al. 21 have also reported delayed bactericidal activity of clofazimine in vitro. Furthermore, if the activity of clofazimine was associated with the need to first saturate host tissues, then in theory this saturation could be achieved more In vitro EBA defined as the decline in log 10 cfu/mL/day during the days indicated in the subscript. Data points represent the mean (SD) from three biological replicates (where EBA values were calculated separately for each replicate), except for the 'Clofazimine 2.0' group, for which there were two biological replicates. Raw cfu count data are presented in Table S1 . Delayed anti-tuberculosis activity of clofazimine JAC quickly with the use of loading doses. In a previous study conducted in M. tuberculosis-infected BALB/c mice, we found that while administration of loading doses did lead to a rapid, dosedependent increase in serum clofazimine levels, the loading doses had no impact on the antimicrobial activity of the drug (compared with non-loading dose regimens), both during the first 2 weeks of treatment as well overall during the 3 months of treatment. 14 In the EBA study conducted in TB patients, clofazimine was administered with a loading dose, but still no EBA was observed, 12 again suggesting that a saturation process in the host cannot explain all of the delayed antimicrobial activity.
In vivo, it could be said that no EBA of clofazimine against M. tuberculosis was observed with any dose administered because the lung cfu counts were higher after 14 days of treatment than at the beginning of treatment (Table 2) . In our experiment, we used an acute infection model in which mice were infected with a relatively high inoculum (implantation of 4 log 10 cfu/lung); treatment was initiated 1 week after infection, when the bacteria were very actively multiplying in the mouse lungs. Thus, in our model, it would be very clear if clofazimine exerted antimicrobial activity against M. tuberculosis, either by killing the bacteria or by stopping their multiplication. During the first week of treatment (again, with any dose of clofazimine), the bacteria continued to multiply as in the lung of the untreated mice, clearly demonstrating no anti-TB activity of clofazimine during this time. However, during the second week of treatment, antimicrobial activity was observed with the 100, 50 and 25 mg/kg doses of clofazimine ( Figure 2) . Previously, in an experiment where clofazimine was added to the first-line regimen and administered to M. tuberculosis-infected BALB/c mice, the addition of clofazimine had no impact on the bactericidal activity of the regimen during the first week of treatment, but then exerted dramatic activity during the second week of treatment, resulting in 2 log 10 cfu more killing than in the non-clofazimine-containing control regimen. 11 Thus, collectively, our data strongly indicate that clofazimine's activity against M. tuberculosis is not evident before 1 week of exposure, regardless of the drug concentration or the dose administered.
A clear concentration-dependent effect was observed in the in vitro experiments in which, after the initial delay in activity, antimicrobial activity was observed such that, at concentrations above the MIC, killing was observed, and, at concentrations at or below the MIC, bacteriostatic activity was observed (Table 1 and Figure 1 ). However, in the infected mice, while serum levels were dose dependent (Figure 2a) , a dose-dependent effect on the antimicrobial activity was less evident (Figure 2b) . No antimicrobial activity was observed throughout the 14 day course of the experiment with clofazimine administered at 12.5 mg/kg or lower doses. Antimicrobial activity was observed with the higher doses (i.e. clofazimine at 25, 50 or 100 mg/kg), but no significant differences in lung cfu counts were observed between these three groups. These data are not dissimilar to a previous study where we found that clofazimine administered in six different dosing schemes, including daily doses of 25, 12.5 or 6.25 mg/kg, resulted in dose-dependent serum and tissue concentrations, but in dose-independent bactericidal activity.
14 Thus, these data again raise a key issue that perhaps clofazimine could be administered at doses lower than the 25 mg/kg 'standard' dose, which is equivalent to the 100 mg daily dose in humans, 22 and still be highly effective. In this current experiment, in vivo antimicrobial activity was observed (after 1 week) in the groups of mice whose serum clofazimine concentrations were above the MIC for M. tuberculosis. As drug carryover was observed in the undiluted lung homogenates from mice that received 12.5 and 6.25 mg/kg clofazimine (Table S2) , there was clearly enough drug in the tissues to inhibit bacterial growth, but it seems that there is a minimum serum concentration that may correlate better with the antimicrobial activity. This hypothesis is further supported by recent data demonstrating that after stopping administration of clofazimine, sustained antimicrobial activity is observed in M. tuberculosis-infected BALB/c mice in relation to the time the serum drug concentration remains above the MIC. 23 Overall, these data indicate that serum clofazimine levels are critical to the antimicrobial activity, but only after a week of exposure; achieving super-MIC serum concentrations faster does not result in faster or improved antimicrobial activity.
Thus a key issue raised by our data is why clofazimine has this observed delay in antimicrobial activity. Likely the delay is related to the mechanism of action of clofazimine, which is poorly understood, but seems to involve interference with the proton motive force and therefore bacterial ATP production by membrane interaction with the respiratory chain and/or phospholipids. 15, 16, 24, 25 In this case, the delayed activity could due to (i) the need to first saturate the lipid-rich bacterial membrane, (ii) the time needed to disrupt the proton motive force and/or (iii) the need to deplete energy stores before antimicrobial activity is observed. The latter mechanism has been proposed as the reason for the similar delayed antimicrobial activity of the ATP-synthase-targeting drug bedaquiline. 24, 25 The data regarding the effect on dose and concentration in relation to clofazimine's antimicrobial activity, both in this study and in a previous study, 14 have been generated in experiments where clofazimine was used alone and not in combination with other drugs. As TB treatment is always administered as multidrug regimens, the impact of clofazimine concentration or dose in combination with other anti-TB drugs must also be examined. We have observed in a number of studies combining clofazimine (at the standard 25 mg/kg dose) with first-line or second-line anti-TB drugs results in 2 log 10 cfu more killing than in the non-clofazimine-containing EBA: decline in mean log 10 cfu/lung/day of treatment (for the days of treatment indicated in the subscript). EBA values were calculated from mean log 10 cfu counts. Raw cfu count data are presented in Table S2 .
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control regimens. 10, 11, 23 This magnitude of bactericidal activity is greater than what has been observed with clofazimine alone; thus, it would be of interest to evaluate how low of a dose of clofazimine can be administered and still contribute potent bactericidal activity to a multidrug regimen.
Finally, our in vitro and in vivo 14 day EBA experiments raise questions about the meaning and interpretation of EBA studies. When the first EBA study was described by Jindani et al. 13 in 1980, EBA was essentially defined to describe the potent and rapid bactericidal activity of isoniazid against M. tuberculosis, evidenced by the rapid decline in sputum cfu counts during the first 2 days of treatment. Even in this original report, the authors cautioned that EBA had a 'remarkably poor correlation' with late sterilizing activity, as the two key sterilizing drugs, pyrazinamide and rifampicin, had no or poor EBA. It is well appreciated that the activity of drugs, especially drugs administered alone, during the first 14 days of treatment cannot provide information about the longterm anti-TB activity. However, the failure of drugs or drug combinations to demonstrate EBA in TB patients is often considered as negative when deciding whether or not to move forward with clinical development or clinical studies. It may be possible to utilize the mouse model to more carefully dissect the early antimicrobial activity of anti-TB drugs in combination with longer-term studies, to provide the best possible preclinical data to guide human studies.
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